The age‐specific prevalence of human papillomavirus and risk of cytologic abnormalities in rural Nigeria: Implications for screen‐and‐treat strategies
dc.contributor.author | Gage, Julia C. | en_US |
dc.contributor.author | Ajenifuja, Kayode O. | en_US |
dc.contributor.author | Wentzensen, Nicolas A. | en_US |
dc.contributor.author | Adepiti, Akinfolarin C. | en_US |
dc.contributor.author | Eklund, Claire | en_US |
dc.contributor.author | Reilly, Mary | en_US |
dc.contributor.author | Hutchinson, Martha | en_US |
dc.contributor.author | Wacholder, Sholom | en_US |
dc.contributor.author | Harford, Joe B. | en_US |
dc.contributor.author | Soliman, Amr S. | en_US |
dc.contributor.author | Burk, Robert D. | en_US |
dc.contributor.author | Schiffman, Mark | en_US |
dc.date.accessioned | 2012-03-16T15:54:59Z | |
dc.date.available | 2013-07-01T14:33:05Z | en_US |
dc.date.issued | 2012-05-01 | en_US |
dc.identifier.citation | Gage, Julia C.; Ajenifuja, Kayode O.; Wentzensen, Nicolas A.; Adepiti, Akinfolarin C.; Eklund, Claire; Reilly, Mary; Hutchinson, Martha; Wacholder, Sholom; Harford, Joe; Soliman, Amr S.; Burk, Robert D.; Schiffman, Mark (2012). "The age‐specific prevalence of human papillomavirus and risk of cytologic abnormalities in rural Nigeria: Implications for screen‐and‐treat strategies ." International Journal of Cancer 130(9): 2111-2117. <http://hdl.handle.net/2027.42/90127> | en_US |
dc.identifier.issn | 0020-7136 | en_US |
dc.identifier.issn | 1097-0215 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/90127 | |
dc.description.abstract | Cervical screening for carcinogenic human papillomavirus (HPV) infection is being considered for low‐income countries. Effectiveness requires targeted screening in older women in whom prevalent infections are more likely to be persistent and predictive of precancer. Some studies in West Africa have found unusually high HPV prevalences across all adult ages, which may reduce the positive predictive value (PPV) of HPV‐based screening, if positivity in older women does not sufficiently predict elevated risk. We conducted a population‐based study in rural Nigeria to identify HPV prevalence and associated cervical abnormalities. Using stratified random sampling, we enrolled women age 15+. Nonvirgins had a cervical exam including liquid‐based cytology and PCR HPV DNA testing from residual cytology specimens. Two‐thirds of invited women participated, and 14.7% had detectable carcinogenic HPV, a proportion that did not decline with age ( p ‐trend = 0.36) and showed slight peaks in the 15–29 and 60–69 age groups. Among women of the age typically considered for screen‐and‐treat programs (30–49 years), 12.8% were HPV positive, and the PPV for high‐grade or worse cytology was 16.4%. Comparatively, women age < 30 were more likely to be HPV positive (18.9%, p = 0.03) with a lower PPV (4.2% p = 0.05). Among women age 50+ (typically excluded from screening in resource‐poor settings because inexpensive treatment is not available), HPV positivity was 14.2% with a PPV of 13.9%. In Irun and similar settings where HPV does not decline with age, HPV‐based screen‐and‐treat programs might be feasible for mid‐adult women because prevalence is sufficiently low and positivity predicts elevated risk of more easily treated precancer. | en_US |
dc.publisher | Wiley Subscription Services, Inc., A Wiley Company | en_US |
dc.subject.other | HPV Prevalence | en_US |
dc.subject.other | Screening | en_US |
dc.subject.other | Age | en_US |
dc.title | The age‐specific prevalence of human papillomavirus and risk of cytologic abnormalities in rural Nigeria: Implications for screen‐and‐treat strategies | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Oncology and Hematology | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI | en_US |
dc.contributor.affiliationother | Department of Pathology and Laboratory Medicine, Women and Infants Hospital, Providence, RI | en_US |
dc.contributor.affiliationother | Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, DHHS, Bethesda, MD | en_US |
dc.contributor.affiliationother | Department of Obstetrics, Gynaecology and Perinatology, Obafemi Awolowo University, Ile‐Ife, Nigeria | en_US |
dc.contributor.affiliationother | Office of International Affairs, National Cancer Institute, National Institutes of Health, DHHS, Bethesda, MD | en_US |
dc.contributor.affiliationother | Department of Pediatrics, Albert Einstein Cancer Center, Albert Einstein College of Medicine, Bronx, NY | en_US |
dc.contributor.affiliationother | Department of Microbiology and Immunology, Albert Einstein Cancer Center, Albert Einstein College of Medicine, Bronx, NY | en_US |
dc.contributor.affiliationother | Department of Obstetrics, Gynecology, and Women's Health, Albert Einstein Cancer Center, Albert Einstein College of Medicine, Bronx, NY | en_US |
dc.contributor.affiliationother | Department of Epidemiology and Population Health, Albert Einstein Cancer Center, Albert Einstein College of Medicine, Bronx, NY | en_US |
dc.contributor.affiliationother | Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics (DCEG), National Cancer Institute, 6120 Executive Blvd, MSC 7231, Rockville, MD 20852, USA | en_US |
dc.identifier.pmid | 21630264 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/90127/1/26211_ftp.pdf | |
dc.identifier.doi | 10.1002/ijc.26211 | en_US |
dc.identifier.source | International Journal of Cancer | en_US |
dc.identifier.citedreference | Kwikkel HJ, Helmerhorst TJ, Bezemer PD, Quaak MJ, Stolk JG. Laser or cryotherapy for cervical intraepithelial neoplasia: a randomized study to compare efficacy and side effects. Gynecol Oncol 1985; 22: 23 – 31. | en_US |
dc.identifier.citedreference | Andersen ES, Husth M. Cryosurgery for cervical intraepithelial neoplasia: 10‐year follow‐up. Gynecol Oncol 1992; 45: 240 – 2. | en_US |
dc.identifier.citedreference | Ferenczy A. Comparison of cryo‐ and carbon dioxide laser therapy for cervical intraepithelial neoplasia. Obstet Gynecol 1985; 66: 793 – 8. | en_US |
dc.identifier.citedreference | Gravitt PE, Burk RD, Lorincz A, Herrero R, Hildesheim A, Sherman ME, Bratti MC, Rodriguez AC, Helzlsouer KJ, Schiffman M. A comparison between real‐time polymerase chain reaction and hybrid capture 2 for human papillomavirus DNA quantitation. Cancer Epidemiol Biomarkers Prev 2003; 12: 477 – 84. | en_US |
dc.identifier.citedreference | Denny L, Kuhn L, Hu CC, Tsai WY, Wright TC, Jr. Human papillomavirus‐based cervical cancer prevention: long‐term results of a randomized screening trial. J Natl Cancer Inst 2010; 102: 1557 – 67. | en_US |
dc.identifier.citedreference | Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189: 12 – 19. | en_US |
dc.identifier.citedreference | Schiffman MH, Bauer HM, Hoover RN, Glass AG, Cadell DM, Rush BB, Scott DR, Sherman ME, Kurman RJ, Wacholder S, Stanton CK, Manos MM. Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J Natl Cancer Inst 1993; 85: 958 – 64. | en_US |
dc.identifier.citedreference | Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meijer CJ. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348: 518 – 27. | en_US |
dc.identifier.citedreference | Ferlay J, Shin H, Bray F, Forman D, Mathers C, Parkin D. GLOBOCAN 2008: cancer incidence and mortality worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer, 2008. | en_US |
dc.identifier.citedreference | Gustafsson L, Ponten J, Zack M, Adami HO. International incidence rates of invasive cervical cancer after introduction of cytological screening. Cancer Causes Control 1997; 8: 755 – 63. | en_US |
dc.identifier.citedreference | .Gustafsson L, Ponten J, Bergstrom R, Adami HO. International incidence rates of invasive cervical cancer before cytological screening. Int J Cancer 1997; 71: 159 – 65. | en_US |
dc.identifier.citedreference | Denny L, Quinn M, Sankaranarayanan R. Chapter 8: Screening for cervical cancer in developing countries. Vaccine 2006; 24 ( Suppl 3 ): S71 – S77. | en_US |
dc.identifier.citedreference | Didelot‐Rousseau MN, Nagot N, Costes‐Martineau V, Valles X, Ouedraogo A, Konate I, Weiss HA, Van de Perre P, Mayaud P, Segondy M. Human papillomavirus genotype distribution and cervical squamous intraepithelial lesions among high‐risk women with and without HIV‐1 infection in Burkina Faso. Br J Cancer 2006; 95: 355 – 62. | en_US |
dc.identifier.citedreference | Castle PE, Schiffman M, Gravitt PE, Kendall H, Fishman S, Dong H, Hildesheim A, Herrero R, Bratti MC, Sherman ME, Lorincz A, Schussler JE, et al. Comparisons of HPV DNA detection by MY09/11 PCR methods. J Med Virol 2002; 68: 417 – 23. | en_US |
dc.identifier.citedreference | Wall SR, Scherf CF, Morison L, Hart KW, West B, Ekpo G, Fiander AN, Man S, Gelder CM, Walraven G, Borysiewicz LK. Cervical human papillomavirus infection and squamous intraepithelial lesions in rural Gambia, West Africa: viral sequence analysis and epidemiology. Br J Cancer 2005; 93: 1068 – 76. | en_US |
dc.identifier.citedreference | Keita N, Clifford GM, Koulibaly M, Douno K, Kabba I, Haba M, Sylla BS, van Kemenade FJ, Snijders PJF, Meijer C, Franceschi S. HPV infection in women with and without cervical cancer in Conakry, Guinea. Br J Cancer 2009; 101: 202 – 8. | en_US |
dc.identifier.citedreference | Thomas JO, Herrero R, Omigbodun AA, Ojemakinde K, Ajayi IO, Fawole A, Oladepo O, Smith JS, Arslan A, Munoz N, Snijders PJF, Meijer C, et al. Prevalence of papillomavirus infection in women in Ibadan, Nigeria: a population‐based study. Br J Cancer 2004; 90: 638 – 45. | en_US |
dc.identifier.citedreference | Franceschi S, Rajkumar R, Snijders PJ, Arslan A, Mahe C, Plummer M, Sankaranarayanan R, Cherian J, Meijer CJ, Weiderpass E. Papillomavirus infection in rural women in southern India. Br J Cancer 2005; 92: 601 – 6. | en_US |
dc.identifier.citedreference | Wu RF, Dai M, Qiao YL, Clifford GM, Liu ZH, Arslan A, Li N, Shi JF, Snijders PJ, Meijer CJ, Franceschi S. Human papillomavirus infection in women in Shenzhen City, People's Republic of China, a population typical of recent Chinese urbanisation. Int J Cancer 2007; 121: 1306 – 11. | en_US |
dc.identifier.citedreference | Goldie SJ, Gaffikin L, Goldhaber‐Fiebert JD, Gordillo‐Tobar A, Levin C, Mahe C, Wright TC. Cost‐effectiveness of cervical‐cancer screening in five developing countries. N Engl J Med 2005; 353: 2158 – 68. | en_US |
dc.identifier.citedreference | Sankaranarayanan R, Nene BM, Shastri SS, Jayant K, Muwonge R, Budukh AM, Hingmire S, Malvi SG, Thorat R, Kothari A, Chinoy R, Kelkar R, et al. HPV screening for cervical cancer in rural India. N Engl J Med 2009; 360: 1385 – 94. | en_US |
dc.identifier.citedreference | Sherman ME, Lorincz AT, Scott DR, Wacholder S, Castle PE, Glass AG, Mielzynska‐Lohnas I, Rush BB, Schiffman M. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10‐year cohort analysis. J Natl Cancer Inst 2003; 95: 46 – 52. | en_US |
dc.identifier.citedreference | Dillner J, Rebolj M, Birembaut P, Petry KU, Szarewski A, Munk C, de Sanjose S, Naucler P, Lloveras B, Kjaer S, Cuzick J, van Ballegooijen M, et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ 2008; 337: a1754. | en_US |
dc.identifier.citedreference | Smith JS, Melendy A, Rana RK, Pimenta JM. Age‐specific prevalence of infection with human papillomavirus in females: a global review. J Adolesc Health 2008; 43: S5 – S25, S25 e1 – e41. | en_US |
dc.identifier.citedreference | Castellsague X, Menendez C, Loscertales MP, Kornegay JR, dos Santos F, Gomez‐Olive FX, Lloveras B, Abarca N, Vaz N, Barreto A, Bosch FX, Alonso P. Human papillomavirus genotypes in rural Mozambique. Lancet 2001; 358: 1429 – 30. | en_US |
dc.identifier.citedreference | Baay MF, Kjetland EF, Ndhlovu PD, Deschoolmeester V, Mduluza T, Gomo E, Friis H, Midzi N, Gwanzura L, Mason PR, Vermorken JB, Gundersen SG. Human papillomavirus in a rural community in Zimbabwe: the impact of HIV co‐infection on HPV genotype distribution. J Med Virol 2004; 73: 481 – 5. | en_US |
dc.identifier.citedreference | Herrero R, Castle PE, Schiffman M, Bratti MC, Hildesheim A, Morales J, Alfaro M, Sherman ME, Wacholder S, Chen S, Rodriguez AC, Burk RD. Epidemiologic profile of type‐specific human papillomavirus infection and cervical neoplasia in Guanacaste, Costa Rica. J Infect Dis 2005; 191: 1796 – 807. | en_US |
dc.identifier.citedreference | Franceschi S, Herrero R, Clifford GM, Snijders PJ, Arslan A, Anh PT, Bosch FX, Ferreccio C, Hieu NT, Lazcano‐Ponce E, Matos E, Molano M, et al. Variations in the age‐specific curves of human papillomavirus prevalence in women worldwide. Int J Cancer 2006; 119: 2677 – 84. | en_US |
dc.identifier.citedreference | Hemmingsson E, Stenson S. The results of cryosurgical treatment in young women with cervical intra‐epithelial neoplasia. Acta Obstet Gynecol Scand 1983; 62: 39 – 42. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.